KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Capital Expenditures (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Capital Expenditures for 12 consecutive years, with -$21000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Capital Expenditures fell 151.22% year-over-year to -$21000.0, compared with a TTM value of $21000.0 through Sep 2022, down 89.6%, and an annual FY2021 reading of $34000.0, down 83.57% over the prior year.
  • Capital Expenditures was -$21000.0 for Q2 2022 at TherapeuticsMD, down from $42000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $996909.0 in Q3 2019 and bottomed at -$70000.0 in Q3 2021.
  • Average Capital Expenditures over 5 years is $172296.5, with a median of $41000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures soared 4745.24% in 2019, then tumbled 638.46% in 2021.
  • Year by year, Capital Expenditures stood at $150745.0 in 2018, then surged by 139.2% to $360587.0 in 2019, then plummeted by 53.41% to $168000.0 in 2020, then tumbled by 141.67% to -$70000.0 in 2021, then skyrocketed by 70.0% to -$21000.0 in 2022.
  • Business Quant data shows Capital Expenditures for TXMD at -$21000.0 in Q2 2022, $42000.0 in Q1 2022, and -$70000.0 in Q3 2021.